Gastrointestinal involvement is common among patients with EGPA, with eosinophilic tissue infiltration, weight loss, and myalgia identified as significant predictors.

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis,” published in the February 2025 issue of American College of Rheumatology by Wechsler et al. Eosinophilic ...

More common side effects in people receiving Nucala for severe eosinophilic asthma, EGPA, or hypereosinophilic syndrome include: Mild side effects can occur with Nucala use. These side effects can ...

Several players from the Brakpan Pool Club will represent the Eastern Gauteng Pool Association (EGPA) at the nationals in Potchefstroom in May. They will compete in several divisions, some in the ...

FTSE EPRA Nareit Developed Pure Asia Total Return Index GBP End Of Day4,220.92‎-0.20% ...